Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Mosliciguat in Familial Hypersensitivity Pneumonitis: NCT07333183 Clinical Landscape Report 2026
16 September 2026
NCT07333183 clinical landscape for Familial Hypersensitivity Pneumonitis: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Plerixafor in Anemia, Sickle Cell: NCT07341022 Clinical Landscape Report 2026
16 September 2026
NCT07341022 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nintedanib esylate in Idiopathic Pulmonary Fibrosis: NCT07344558 Clinical Landscape Report 2026
16 September 2026
NCT07344558 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tegacorat in Muscular Dystrophy, Duchenne: NCT07347548 Clinical Landscape Report 2026
16 September 2026
NCT07347548 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ketamine Hydrochloride in Vaso-occlusive crisis: NCT07369024 Clinical Landscape Report 2026
16 September 2026
NCT07369024 clinical landscape for Vaso-occlusive crisis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ripertamab in Myasthenia Gravis: NCT07372807 Clinical Landscape Report 2026
16 September 2026
NCT07372807 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
NB-4746 in Amyotrophic Lateral Sclerosis: NCT07369076 Clinical Landscape Report 2026
16 September 2026
NCT07369076 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
L-Glutamine in Hemoglobin SC Disease: CTRI/2026/01/102147 Clinical Landscape Report 2026
16 September 2026
CTRI/2026/01/102147 clinical landscape for Hemoglobin SC Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
![[11C]HSP990 in Alzheimer Disease: NCT07380204 Clinical Landscape Report 2026](https://synapse-static.patsnap.com/strapi-static/Blog_cover_B_86_48077a7b89.jpg)
9 min read
[11C]HSP990 in Alzheimer Disease: NCT07380204 Clinical Landscape Report 2026
16 September 2026
NCT07380204 clinical landscape for Alzheimer Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pociredir in Semicircular Canal Dehiscence: NCT07401823 Clinical Landscape Report 2026
16 September 2026
NCT07401823 clinical landscape for Semicircular Canal Dehiscence: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Universal allogeneic anti-CD19/BCMA CAR T-cells(Hematology Hospital of Chinese Academy of Medical Sciences) in Neuromyelitis Optica: NCT07392528 Clinical Landscape Report 2026
16 September 2026
NCT07392528 clinical landscape for Neuromyelitis Optica: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Riluzole in Amyotrophic Lateral Sclerosis: NCT07414212 Clinical Landscape Report 2026
16 September 2026
NCT07414212 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.